全人源BCMA CAR-T治疗复发/难治性多发性骨髓瘤的1期试验及5年随访
FCARH143是一种含全人源BCMA特异性单链可变片段和4-1BB共刺激域的自体BCMA靶向CAR-T疗法,在1期试验中评估用于复发/难治性多发性骨髓瘤。28例入组患者中25例接受输注,中位随访67.3个月,治疗患者总缓解率100%,严格完全缓解64%,中位无进展生存期15.5个月,中位总生存期32.1个月,安全性可控。
要点
- 25例治疗患者总缓解率100%,严格完全缓解率64%。
- 中位无进展生存期15.5个月,中位总生存期32.1个月。
- 细胞因子释放综合征发生率84%,3-4级8%;神经毒性24%,3级12%。
核心结论
- FCARH143显示出强效抗骨髓瘤活性,缓解率100%且毒性可控,不依赖疾病负荷或细胞遗传学风险。
- 作者认为需在高危复发/难治性多发性骨髓瘤中进一步评估。
研究设计与样本
- 1期试验评估自体BCMA靶向CAR-T疗法FCARH143,含全人源BCMA特异性单链可变片段和4-1BB共刺激域。
- 患者按骨髓浆细胞浸润程度(10%-30%或>30%)分层,接受淋巴细胞清除化疗后输注递增剂量CAR-T(50×10^6至450×10^6)。
- 主要终点为安全性;次要终点为总缓解率、缓解持续时间和无进展生存期。
- 共入组28例,均完成白细胞分离和CAR-T制备,其中3例(11%)未进行输注。
- 25例治疗患者中位年龄64岁,中位既往治疗线数8线,80%为三类难治,44%伴髓外病变。
主要发现
- 细胞因子释放综合征发生于84%(3-4级8%,无5级),神经毒性发生于24%(3级12%,无4-5级)。
- 无治疗相关死亡。
- 中位随访67.3个月,治疗患者总缓解率100%,其中严格完全缓解64%。
- 治疗患者中位无进展生存期15.5个月,中位总生存期32.1个月。
- 意向治疗分析(中位随访69.6个月)总缓解率89.3%,总生存期30.2个月。
局限性
- 作者认为需在高危复发/难治性多发性骨髓瘤中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FCARH143, an autologous B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell (CAR-T) therapy, which incorporates a fully human BCMA-specific single chain variable fragment and 4-1BB costimulatory domain, was evaluated in a phase 1 trial for relapsed/refractory multiple myeloma (RRMM). Patients were stratified by bone marrow plasma cell involvement (10%-30% or >30%) and received lymphodepleting chemotherapy followed by escalating CAR-T doses (50 × 106 to 450 × 106). The primary end point was safety; secondary end points were overall response rate (ORR), duration of response, and progression-free survival (PFS). Among 28 enrolled patients, all underwent leukapheresis and successful CAR-T manufacturing, although 3 (11%) did not proceed to infusion. The 25 treated patients (median age, 64 years) had a median of 8 prior therapies, 80% were triple-class refractory, and 44% had extramedullary disease. Cytokine release syndrome occurred in 84% (8% grade 3-4 and no grade 5), and neurotoxicity in 24% (12% grade 3 and no grade 4-5). No treatment-related deaths occurred. At a median follow-up of 67.3 months, treated patients had an ORR of 100%, including a stringent complete response in 64%. Median PFS and overall survival (OS) were 15.5 and 32.1 months, respectively. In an intention-to-treat analysis (median follow-up, 69.6 months), the ORR was 89.3%, and OS was 30.2 months. FCARH143 demonstrated potent antimyeloma activity, with a 100% response rate and manageable toxicity, independent of disease burden or cytogenetic risk. Further evaluation in high-risk RRMM is warranted. This trial was registered at www.clinicaltrials.gov as #NCT03338972.
引用
- Tuazon SA, Portuguese AJ, Pont MJ, et al. A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up. Blood. 2025. PMID: 40198877. doi:10.1182/blood.2024027681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。